Clinical Policy: ACEI and /ARB Duplicate Therapy
Reference Number: CP.PMN.61
Effective Date: 08/14
Last Review Date: 05/17
Line of Business: Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
The intent of the criteria is to ensure that patients follow selection elements established by Centene medical policy for angiotensin-converting enzyme inhibitor (ACEI) and /angiotensin receptor blocker (ARB) ~~(ACEI/ARB)~~ duplicate therapy.

~~**FDA approved indication**~~
~~N/A~~

Policy/Criteria
Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria

It is the policy of health plans affiliated with Centene Corporation® that ACEI and /ARB duplicate therapy is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. ACEI and /ARB Duplicate Therapy (must meet all~~1, 2 and 4 or 2, 3, and 4~~**):**

1. Member meets one of the following (a or b):
   a. ~~Request is for continuity of care for m~~Member~~s~~ is currently receiving ACEI and ARB combination therapy for ~~with a diagnosis of~~ chronic heart failure ~~that are stabilized on~~, has received the combination for at least 30 days, and is responding positively to therapy without adverse outcomes;
   ~~1.~~b. Member is being titrated to, or tapered from another ACEI or ARB;
2. ~~—~~Provider documents that he/she is aware of duplicative therapy;
3. ~~2.Member is being titrated to, or tapered from another ACE Inhibitor or ARB;~~
4. ~~3.~~Dose does not exceed the FDA approved maximum recommended dose for the relevant ACEI and ARB ~~limit~~.

Approval duration: 12 months ~~for chronic heart failure; 3 months for cross-taper or the requested length of therapy (for titration/tapering)~~

~~**B. Other diagnoses/indications**~~

~~1. N/A~~

II. Continued Therapy

A. ACEI and /ARB Duplicate Therapy (must meet all)**:**

1. Currently receiving ~~medication~~ ACEI and ARB combination therapy via Centene benefit or member has previously met ~~all~~ initial approval criteria;
2. Documentation of positive response to therapy;

Formatted: Indent: Left: 0.75"

Formatted: Indent: Left: 0.75"

Formatted: Normal, No bullets or numbering

2.3. ~~Dose~~ If request is for a dose increase, new dose do~~do~~es not exceed FDA approved maximum recommended ~~limi~~dose for the relevant ACEI and ARB~~t~~.

Approval duration: 12 months for chronic heart failure; one additional 3-month approval for cross-taper (6 months total for cross-taper)

~~**B. Other diagnoses/indications** (must meet 1 or 2)~~**:**

~~1. N/A~~

~~**III. Diagnoses/Indications for which coverage is NOT authorized:**~~

~~**A. N/A**~~

~~IV.~~III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ACEI: angiotensin-converting enzyme inhibitor
ARB: angiotensin receptor blocker
FDA: Food and Drug Administration
~~N/A: not applicable~~

~~V.~~IV. Dosage and Administration

~~N/A~~

Agent	Maximum Dose
ACEIs	
Benazepril (Lotensin)	80 mg/day
Captopril (Capoten)	450 mg/day
Enalapril (Vasotec, Epaned)	40 mg/day
Fosinopril (Monopril)	80 mg/day
Lisinopril (Prinivil, Zestril, Qbrelis)	80 mg/day
Moexipril (Univasc)	30 mg/day
Perindopril (Aceon)	16 mg/day
Quinapril (Accupril)	80 mg/day
Ramipril (Altace)	20 mg/day
Trandolapril (Mavik)	8 mg/day
ARBs	
Azilsartan (Edarbi)	80 mg/day
Candesartan (Atacand)	32 mg/day
Eprosartan (Teveten)	900 mg/day
Irbesartan (Avapro)	300 mg/day
Losartan (Cozaar)	100 mg/day
Olmesartan (Benicar)	40 mg/day
Telmisartan (Micardis)	80 mg/day
Valsartan (Diovan)	320 mg/day

~~VI.~~V. Product Availability

ACEIs	ARBs

Formatted: Indent: Left: 0.5"

Formatted: Font: Bold

Formatted: Numbered + Level: 1 + Numbering Style: I, II, III, … + Start at: 1 + Alignment: Right + Aligned at: 0" + Indent at: 0.25"

Formatted: Font: Bold, Font color: Black

Formatted: Indent: Left: 0.5"

Formatted: Font: Bold

Formatted: Numbered + Level: 1 + Numbering Style: I, II, III, … + Start at: 1 + Alignment: Right + Aligned at: 0" + Indent at: 0.25"

Formatted: Indent: First line: 0.25"

Benazepril (Lotensin)	Azilsartan (Edarbi)
Captopril (Capoten)	Candesartan (Atacand)
Enalapril (Vasotec, Epaned)	Eprosartan (Teveten)
Fosinopril (Monopril)	Irbesartan (Avapro)
Lisinopril (Prinivil, Zestril, Qbrelis)	Losartan (Cozaar)
Moexipril (Univasc)	Olmesartan (Benicar)
Perindopril (Aceon)	Telmisartan (Micardis)
Quinapril (Accupril)	Valsartan (Diovan)
Ramipril (Altace)	
Trandolapril (Mavik)	

~~VII.~~VI. Workflow Document

CP.PMN.61.ACEI and ARB duplicate t

Field Code Changed

~~VIII.~~VII. References

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at: http://www.clinicalpharmacology-ip.com/. ~~Drug Monographs. Clinical Pharmacology. Accessed March 2016 http://www.clinicalpharmacology-ip.com.~~
~~2.~~ Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013;346:f360.
~~3. Prescribing information (drug specific).~~
~~4.~~2. ~~Combining ACEIs ARBs or Aliskiren: The Pharmacist's Letter 2013; 29(3):290301.~~
~~5.~~ Fried LF, Emanuele N, Zhang JH, ~~-~~et al. Combined a~~A~~ngiotensin i~~I~~nhibitor t~~T~~reatment of d~~D~~iabetic n~~N~~ephropathy. N Engl J Med 2013; 369(20).
~~6.~~3. ~~Townsend RR. Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Bakris GL, Kaplan NM (Ed), UpToDATE. Waltham MA. Accessed March 2016.~~
4. Mann JF, Schmieder RE, McQueen M, ~~-~~et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study); a multicentre, randomized, double-blind, controlled trial. Lancet. 2008;372(9638):547-53.
~~7.~~5. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in AdultsReport From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427. ~~5.~~

Formatted: Space After: 0 pt, Line spacing: single

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Updated references to reflect current literature search	08/14	08/14
Converted to new template;	03/16	05/16

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Added FDA dosage limit; Updated references.		
~~No clinical changes made to criteria~~ -Converted to new template -Added duration of 30 days to initial requirement related to continuity of care/heart failure for clarity -Specified approval duration of 3 months for cross-taper for initial and re-auth; limited approval duration for cross-taper to total of 6 months Added documentation of positive response to therapy on re-auth Updated references	03~~1~~/17	05/17

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise

professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.